BioSpace News Archive

Health Canada is informing Canadians that Allergan Inc. has decided to withdraw the drug Fibristal (ulipristal acetate), used to treat uterine fibroids, from the Canadian market.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, will present at the H.C. Wainwright 4th Annual NASH Investor Conference on Monday, October 5, 2020 at 4:30 p.m. ET.

Application Being Reviewed Under FDA’s Real-Time Oncology Review (RTOR) Pilot Program

National Health Investors, Inc. (NYSE:NHI) today announced that it has exercised its purchase option to acquire The Courtyard at Bellevue, a 43-unit assisted living and memory care community in Bellevue, WI.

Gamma Biosciences, a life sciences tools platform created by KKR, today announced that it has acquired Nanopareil LLC, a South Dakota, US-based company developing next-generation nanofiber membrane products for chromatographic separation in bioproduction.

Theralase® Technologies Inc., a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 3,157,059 share purchase warrants, all of which are exercisable at $0.50 per share.

Pacgen Life Science Corporation (“Pacgen” or the “Company”) (TSX-V: PBS) is pleased to announce it has completed a statutory plan of arrangement (the “Arrangement”) under the Business Corporations Act (British Columbia) pursuant to which General Biologicals Corporation (“GBC”) has acquired all of the issued and outstanding common shares of the Company (“Pacgen Shares”),

Spero Therapeutics, Inc. announced that on September 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,000 shares of its common stock to four new employees under the Spero Therapeutics, Inc.

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the phase 2 COMPARE study comparing the efficacy of SEL-212, a combination of Selecta’s tolerogenic ImmTOR™ immune tolerance platform and a therapeutic uricase enzyme (pegadricase), to pegloticase (KRYSTEXXA®), the currently approved uricase in th

Mitsubishi Electric Corporation announced that construction of its SUSTIE net zero-energy building test facility located on the premises of the company’s Information Technology R&D Center in Kamakura, Japan, will be completed on October 14.